A memorandum of understanding was signed at the Abu Dhabi Future Health Summit between Burjeel Holdings and Britain’s Avatrial to integrate artificial intelligence and molecular analytics in discovering new therapeutic targets for tumors.
Signing of the MoU between Burjeel and Avatrial at the Abu Dhabi Future Health Summit
Integrating multi-layered molecular analytics and laboratory models
Clinical sample governance and the roles of the Burjeel Cancer Institute and Nurion
The importance of regional biodiversity and the scientific steps required for implementation
Frequently asked questions
Signing of the MoU between Burjeel and Avatrial at the Abu Dhabi Future Health Summit
Abu Dhabi-based Burjeel Holdings signed a memorandum of understanding on October 20, 2026, with British biotechnology company Avatrial to explore the development of an integrated AI-assisted cancer drug discovery framework in the emirate. According to the Emirates News Agency, the agreement was signed during the Abu Dhabi Future Health Summit by Dr. Khaled Moslem, Chief Research Officer at Burjeel, and Dr. Kourosh Saeb-Parsy, founder of Avatrial, in the presence of Dr. Shamsheer Vayalil, Chairman and Managing Director of Burjeel Holdings.
While this proposed collaboration brings together the research and clinical assets of both companies, it currently stands as a framework agreement to explore cooperation and does not establish a finalized, complete clinical trial or a marketed drug.
Integrating multi-layered molecular analytics and laboratory models
Through this partnership, both parties aim to connect clinical information, molecular analytics, and empirical research to identify potential therapeutic targets for cancer. Burjeel Holdings contributes its local clinical operations and extensive expertise in oncology research, while Avatrial provides artificial intelligence technologies, multi-layered biological analysis techniques, and patient-derived laboratory models.
Multi-layered biological analysis examines various levels of biological information, including genes, molecular activity, and protein-related measurements, with the goal of improving precise scientific understanding of disease progression processes. According to the announcement, ethically approved surplus tumor samples and de-identified clinical information may be used for research purposes following regulatory and ethical approvals. AI-supported classification will help prioritize promising therapeutic targets for testing via experimental laboratory models rather than relying solely on algorithmic computational predictions.
Clinical sample governance and the roles of the Burjeel Cancer Institute and Nurion
Patient biological materials and clinical samples are highly sensitive; therefore, the agreement’s references to ethical approval, de-identification, and regulatory review are essential conditions, though they represent preliminary commitments regarding the proposed work rather than proof that all databases have been compiled or final licenses issued for each individual study.
Burjeel Holdings identified both the Burjeel Cancer Institute and its clinical research organization Nurion as potential contributors to the development of future research programs and clinical trials within a model connecting laboratory discovery to the medical clinic. However, any drug compound showing favorable performance in preclinical research will still require separate development agreements, safety tests, human clinical trials, and independent regulatory review.
The importance of regional biodiversity and the scientific steps required for implementation
The partners expressed their ambition to develop evidence-based treatments involving actual patients in the Middle East region, which could help enrich the diversity of biological and clinical data used in global medical research. However, the press release did not indicate a novel biomarker, identify a discovered drug target, disclose funding amounts, or reveal independent results from the joint platform.
The description of this model potentially becoming the first of its kind regionally must remain attributed to the partners, as it does not rule out other AI-backed oncology research in the region. Tangible upcoming milestones include adopting research protocols, conducting actual studies, and publishing scientific verification results.
This planned research collaboration between Burjeel Holdings and Britain’s Avatrial represents an important step toward localizing advanced drug discovery technologies in the Emirate of Abu Dhabi, particularly in cancer treatment, which requires close integration between genetic and molecular data and on-the-ground clinical expertise. Rather than merely importing ready-made therapeutic solutions, the joint model—incorporating the Burjeel Cancer Institute and Nurion—seeks to build a biological database reflecting the genetic characteristics of patients in the region and translate AI computational analysis outputs into testable laboratory therapeutic hypotheses.
Frequently asked questions
Question: What does the memorandum of understanding signed between Burjeel Holdings and Britain’s Avatrial entail?
Answer: It involves exploring the development of an AI-assisted cancer drug discovery ecosystem in Abu Dhabi by linking clinical data with multi-layered molecular analysis and laboratory models.
Question: Where was the agreement signed, and who were the key signatories and attendees?
Answer: The agreement was signed at the Abu Dhabi Future Health Summit on October 20, 2026, by Dr. Khaled Moslem of Burjeel and Dr. Kourosh Saeb-Parsy, founder of Avatrial, in the presence of Dr. Shamsheer Vayalil.
Question: What Burjeel Holdings institutions will participate in the project?
Answer: The company identified both the Burjeel Cancer Institute and the clinical research organization Nurion to contribute to the development of future research programs and clinical trials.
Question: How does the project combine artificial intelligence with laboratory experiments?
Answer: Artificial intelligence analyzes genetic, molecular, and protein data to prioritize potential therapeutic targets, after which promising candidates are practically tested via laboratory models derived from patient samples following ethical approvals.